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Abstract:  Alcohol  use disorders and alcohol dependency affect millions of individuals 
worldwide.  The  impact  of  these  facts  lies  in  the  elevated  social  and  economic  costs. 
Alcoholic liver disease is caused by acute and chronic exposure to ethanol which promotes 
oxidative stress and inflammatory response. Chronic consumption of ethanol implies liver 
steatosis, which is the first morphological change in the liver, followed by liver fibrosis and 
cirrhosis. This review comprises a broad approach of alcohol use disorders, and a more 
specific  assessment  of  the  pathophysiologic  molecular  basis,  and  genetics,  as  well  as 
clinical presentation and current modalities of treatment for alcoholic liver disease.  
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1. Introduction 
Alcohol dependency (AD) is a complex addictive disorder, affecting millions of individuals around 
the  world  each  year.  AD  is  considered  a  worldwide  public  health  problem  with  a  direct  causal 
relationship between alcohol consumption and more than 60  different types of disease and injury. 
Regarding this, the ICD-10 (International Classification of Disease 10th Revision) has reported eight 
causes of death related to alcohol consumption (Table 1). Most of these causes are related to the 
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amount and time of exposure to alcoholic beverages. According to the World Health Organization, the 
average alcohol consumption per capita in adults is 5.1 liters per year, though mean consumption 
varies worldwide. While in some countries, like Saudi Arabia, alcohol consumption (liters per capita 
per year) is 0.0, in other countries such as Luxembourg the consumption reaches 17.54 [1]. 
Table 1. Causes of death related to alcohol abuse. 
1  Mouth and oropharynx cancer 
2  Alcohol use disorders 
3  Ischemic heart disease 
4  Liver cirrhosis 
5  Road traffic accidents 
6  Poisonings 
7  Falls 
8  Intentional injuries 
 
The impact and consequences of AD and alcohol abuse have elevated economical costs, as well as 
negative health and social implications. The most direct health influence of ethanol consumption is 
reflected in a systemic level; thereby moderate ethanol consumption has been related to a reduced 
cardiovascular disease, favorable lipid profile and less thrombogenic platelet function [2]. On the other 
hand, elevated amounts of alcohol intake lead to hepatic damage.  
Although the mechanisms by which ethanol causes liver damage have been well described, some 
facts  remain  to  be  elucidated.  The  risk,  severity  and  prognosis  of  ethanol-mediated  liver  diseases 
generally  depend  on  the  amount,  frequency,  and  duration  of  alcohol  consumption,  as  well  as  the 
continued presence of liver inflammation, diet, nutritional status and genetic make-up of the host. In 
this matter, alcoholic steatosis (AS) is the initial pathology found in early stages of the natural history 
of  alcoholic  liver  disease  (ALD).  AS  is  characterized  by  the  accumulation  of  lipids  in  the  liver. 
Steatosis caused by alcohol is clinically considered as benign since it is reversible if the stimulus is 
removed.  The  progression  to  alcoholic  steatohepatitis  (ASH)  represents  the  key  step  in  the 
development of ALD. Only a small portion of heavy drinkers develop a severe form of the disease, 
suggesting the involvement of other factors modifying ALD onset and presentation [3]. 
Alcohol is identified as a harmful agent to the liver, and hepatic stellate cells (HSC) are activated in 
response to this injury. Activated HSC are recognized as fibrogenic cells and lead to deposition of 
collagen (particularly collagen type I). HSC are also regulated in a paracrine manner by acetaldehyde 
and  reactive  oxygen  species  (ROS),  produced  by  the  metabolism  of  ethanol  in  surrounding 
hepatocytes. Activated Kupffer cells secrete pro-inflammatory cytokines, linking apoptosis in the liver 
to inflammation [4]. 
―Programmed cell death‖, also  called apoptosis, plays  an important  role in the pathogenesis of 
chronic liver disease. Whenever there is an acute presentation of the disease, it is possible to observe 
massive hepatocyte apoptosis. This phenomenon induces progressive fibrosis, which is the hallmark of 
chronic  liver  damage  and,  therefore  could  result  in  liver  failure,  cirrhosis,  and  
hepatocellular carcinoma.  Int. J. Environ. Res. Public Health 2010, 7                 
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To objectively assess damage degree in the hepatic parenchyma, completion of a histological study 
is  required.  In  steatohepatitis,  findings  in  the  lamellae  include  hepatocyte  steatosis,  ballooning, 
apoptosis,  and  lobular  inflammatory  infiltrate  [4].  When  ALD  is  established,  an  accumulation  of 
reducing  equivalents  in  the  cytosol  and  the  rates  of  fatty  acids  biosynthesis  and  subsequent 
esterification into triglycerols are markedly increased [5]. 
2. Assessing the Problem 
The  World  Health  Organization  reports  about  two  billion  alcohol  consummers  worldwide  and  
76.3 million people with diagnosable alcohol use disorders [1]. Globally, alcohol causes 3.2% deaths 
for all causes (1.8 million deaths annually) and accounts for 4.0% of disease burden [2]. 
Excessive ethanol consumption is an important preventable cause of morbidity. The association 
between ethanol intake and alcoholic liver disease has been well documented, though liver cirrhosis 
develops only in a small proportion of heavy drinkers. Twenty percent of alcoholics and heavy drinkers 
develop fatty liver and only 10 to 15 percent of these will develop cirrhosis. The point prevalence of 
cirrhosis is 1% in people who drink 30 to 60 g of alcohol a day, and up to 5.7% in those consuming 
120 g daily. In this matter, mortality studies have demonstrated that heavy drinkers and alcoholics die 
from cirrhosis at a much higher rate than the general population [6].  
A clear aggregated environmental risk factor for the development of cirrhosis attributable to alcohol 
consumption is infection with hepatitis C virus (HCV). The risk of cirrhosis in humans infected with 
HCV increases proportionally with consumption of more than 30 g of alcohol per day; as mentioned 
above, the highest risk is associated with consumption of more than 120 g per day. Other factors, such 
as sex, genetic characteristics, and environmental influences (including chronic viral infection), play a 
role in the genesis of ALD [7]. 
In addition, alcoholism is a multifactorial brain disorder, according to the DSMIV (Diagnostic and 
Statistical Manual of Mental Disorders Fourth Revision), therefore the approach should be addressed 
on neurobiological and genetic strategies for the prevention, diagnosis, and treatment of alcoholism. 
The  identified  factors  that  contribute  to  the  development  of  alcoholism  are  included  in  a  social 
environment (i.e., parents, family, friends, peers, community, society). Possible social co-determinants 
such  as  poverty,  social  inequality,  and  easy  availability  of  alcoholic  beverages  might  establish 
alcoholism development.  
Several studies indicate that AD has a genetic component. The heritability of alcohol dependence is 
rather high, ranging between 50% and 60%, though it has been shown to be a complex polygenic 
disorder. There have been associated specific genes and polymorphisms that affect the risk of alcohol 
use disorders. These genes involve expression of enzymes responsible for alcohol metabolism, such as 
alcohol dehydrogenase and aldehyde dehydrogenase; those associated with disinhibition, and those that 
confer a low sensitivity to alcohol [8]. 
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3. Genetic Predisposition 
Genes have been proposed to be involved in a predisposition to ALD development and alcohol use 
disorders.  Combined  genetic  information  about  these  two  entities  might  enhance  alcohol  
related diseases.  
3.1. Candidate Genes Predisposing Alcoholic Liver Disease 
When  ethanol  is  consumed,  its  metabolism  depends  almost  exclusively  on  the  liver  through 
different enzymes capable of catalyzing the oxidation of alcohol. Polymorphisms in the two main 
enzymes  involved  in  ethanol  metabolism  [alcohol  dehydrogenase;  1B  (ADH1B)  and  aldehyde 
dehydrogenase  (ALDH2)]  confer  susceptibility  to  develop  ALD.  Alcohol  is  transformed  into 
acetaldehyde through alcohol dehydrogenases, this intermediate metabolite is responsible for the toxic 
effects of ethanol. The next step is the metabolism of acetaldehyde to acetate (a non-toxic metabolite) 
through  ALDH2  [9].  Either  higher  activity  of  ADH1B  or  lower  activity  of  ALDH2  lead  to 
accumulation of acetaldehyde following alcohol consumption, which, in turn, causes an unpleasant and 
aversive response, termed the flushing reaction, similar to the disulfiram effect [10]. Japanese, Chinese 
and some Jewish population constitute the main group displaying specific protective polymorphisms 
against the development of ALD [11]. 
3.2. Candidate Genes Predisposing Alcohol Use Disorders 
Linkage studies have identified several chromosomal regions, supporting the involvement of loci on 
chromosomes  in  alcohol  dependency,  however  the  recognition  of  specific  gene  regions  is  
still challenging.  
3.2.1. Endophenotypes 
It  is  possible  that  a  small  number  of  genes  might  directly  influence  alcohol  dependency. 
Nevertheless,  it  is  more  likely  that  relevant  genes  affect  a  range  of  endophenotypes  (defined  as 
genetically  influenced  intermediate  characteristics).  These  endophenotypes  will  subsequently  have 
impact in the risk for heavier drinking and alcohol-related life problems. Some of these genetically 
influenced characteristics are related to alcoholism, focused in treatment response [12]. In contrast to 
what happens with protective polymorphism in ALD, a low response to alcohol predicts increased risk 
of developing alcohol use disorders and has been associated with genetic variation in the serotonin 
transporter gene and the gene encoding γ-aminobutyric acid receptor A (GABRA) [11]. 
It has also been suggested that a determined gene—environmental interaction contributes to the 
development of AD. This occurs when exposure to an environmental factor has an effect on the health 
of  individuals  which  is  conditioned  to  their  genotype.  Thus,  several  genes  have  been  described 
including  monoamine  oxidase  A  (MAOA),  the  serotonin  transporter  (HTT),  catechol-O-
methyltransferase (COMT), the corticotropin releasing hormones receptor 1 gene and the dopamine 
transporter [8,11,13–15]. The D2 dopamine receptor gene is the most widely studied and described 
receptor related to alcoholism [16]. One study showed that the prevalence of the DRD2 minor allele A1 
(A1/A1  or  A1/A2  genotype)  was  significantly  higher  in  alcoholics  than  in  nonalcoholic  controls  Int. J. Environ. Res. Public Health 2010, 7                 
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(p = 0.001). Mutations in two regions of the DRD2 gene (TaqI A and TaqI B), are associated with 
alcoholism and other drug use disorders [13]. Regarding this matter, a RFLP in the TaqI A1 allele is 
strongly associated with severe alcoholism. Another study demonstrated that the frequency of the A1 
allele at DRD2 in descendants of alcoholic parents was significantly higher than in children of non 
alcoholics. It was also shown a significant association between the genotype at DRD4 and the children 
of alcoholic patients [16]. Although there is a wide range of candidate genes related to alcoholism, 
further studies are needed, not only to elucidate the genetic etiology of this entity, but to decipher 
therapeutic targets. 
4. Pathophysiology 
Mechanisms implicated in alcohol-induced liver damage involve many biochemical reactions with 
different  simultaneous  pathways  interacting  with  each  other.  These  mechanisms  involve  enzymes, 
ROS, endotoxins, cytokines, immune system cells, and genetic predisposition to develop alcoholic 
liver disease [17,18]. Alcohol is metabolized by oxdative reactions to acetaldehyde and then converted 
to acetate through alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH). ADH is 
quantitatively  the  most  important  enzyme  capable  of  catalysing  the  conversion  of  ethanol  
to acetaldehyde.  
Figure  1. Main molecular mechanisms by which ethanol causes oxidative stress. NAD 
Nicotinamide  adenine  dinucleotide,  NADH  reduced  form  of  NAD,  AMP-K  Adenosine 
monophosphate  protein  kinase,  ROS  Reactive  oxygen  species,  ADH  Alcohol 
dehydrogenase, ALDH Acetaldehyde dehydrogenase. 
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It has been proposed that ethanol metabolism causes proteasome inhibition [19] and that the initial 
molecular  changes  of  ethanol  injury  are  the  reduction  of  both  phosphorylation  and  activity  of  
AMP-dependent protein kinase (AMPK). This contributes to the development of fatty liver by allowing 
increased  activity  of  acetyl-CoA  carboxylase  [20,21].  Although  alcoholic  fatty  liver  resolves  with 
alcohol abstinence, steatosis predisposes to the development of hepatic fibrosis and cirrhosis in people 
with continued pathological drinking patterns (Figure 1) [6].  
Wu  et  al. mention  that several mechanisms contribute to alcohol-induced liver injury, and that 
ethanol-induced  oxidative  stress  is  likely  to  arise  from  several  sources,  including  CYP2E1, 
mitochondria, and activated Kupffer cells [17,22]. A central pathway appears to be the induction of 
cytochrome P450 2E1. It metabolizes and activates many toxicological substrates, including ethanol, to 
more reactive and toxic products [23]. This mechanism plays a role in creating a harmful condition 
known as oxidative stress, defined as the result of an imbalance between pro-oxidant and antioxidant 
systems [20]. This enhances the formation of free radicals which act in the lipidic wall membrane 
ongoing lipid peroxidation.  
ROS  are  intermediates  in  cell  signaling  pathways  that  alter  gene  expression  and  lead  to  cell 
proliferation, migration, and apoptosis; thus contribute to the development of chronic ethanol-induced 
liver injury [23]. When alcohol is consumed, CYP2E1 generates acetaldehyde as well as ROS in the 
cytosol of the cell, leading to an increase in oxidative stress with a probable mitochondrial origin. ROS 
are toxic to cells because they can react with most cellular macromolecules by inactivating enzymes or 
denaturing proteins, which causes DNA damage [6]. 
When alcohol is metabolized to acetaldehyde, the oxidized form NAD converts to the reduced form 
NADH.  This  reaction  generates  an  excess  of  reduced  equivalents  which  stimulates  lipid  
biosynthesis  [24].  Alcohol  exposure  increases  nitrosative  stress  with  elevated  levels  of  
ethanol-inducible CYP2E1, nitric oxide synthase, nitrite and mitochondrial hydrogen peroxide. Ethanol 
can  also  induce  and/or  activate  inducible  nitric  oxid  synthase  (iNOS),  which  plays  a  key  role  in 
worsening  alcohol-mediated  hepatotoxicity.  Moreover,  the  overexpression  of 
CYP2E1 aggravates hepatic injury. Besides, expression of cytokeratins 8 and 18 can be considered as 
biomakers for ALD progression [25].  
Alcohol  intake  also  increases  gut  permeability,  allowing  bacterial  endotoxins  to  enter  the 
bloodstream and liver, where it can activate certain immune cells. Lipopolysaccharide (LPS) is an 
important activator of Kupffer cells requiring three cell proteins to complete the process: CD14, TLR4, 
and MD2. Activated Kupffer cells are responsible for an increased expression of TNFα and multiple 
inflammatory cytokines [26]. TNF-α is a mediator, not only in the early stages of fatty liver disease but 
also in the transition to more advanced stages of liver damage [27]. This activation is one of the earliest 
liver responses to injury. TNF-α is considered one of the most important cytokines involved in the 
pathogenesis of alcoholic liver bruise. Evidence indicates that disruption of the TNF-αR1 gene or 
treatment with a TNF-α neutralizing antibody, reduces alcoholic liver injury in mice.  
Alcohol-induced  liver  damage  also  depends  on  the  host  immune  system  susceptibility.  Several 
studies have suggested that immune response plays a role in alcoholic liver disease. Pritchard et al. 
suggested  the  hypothesis  that  activation  of  the  complement  is  required  for  the  development  of  
ethanol-induced fatty liver. They found that C3 contributed to accumulation of triglyceride in the liver, Int. J. Environ. Res. Public Health 2010, 7                 
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while C5 was involved in inflammation and injury to hepatocytes [28]. Another study demonstrated 
that NK cells may also directly ameliorate hepatic fibrosis, first by releasing antifibrotic cytokines 
(interferon [IFN]α and IFNγ), and second by killing activated stellate cells. Ethanol impairs the ability of 
NK cells to kill activated HSC. As a result, it could remove this break in the development of fibrosis 
(Figure 2) [29]. 
Figure 2. NK Natural killer, TNF- Tumor Necrosis Factor alpha, LPS Lipopolysaccharide. 
 
 
Moreover, there are some underlying conditions in which ethanol can cause damage in a broader 
manner.  Thereby,  ethanol  and  chronic  HCV  infection  synergistically  accelerate liver injury.  The 
process by which this occurs remains unclear, but it is believed that chronic liver inflammation is the 
keyhole to this pathogenesis. In these cases, there is a relationship between increased alcohol intake 
and decreased response to interferon (IFN) therapy for HCV [7]. 
Chronic consumption of alcohol elevates iron levels in the body, not only when consuming iron-rich 
beverages like wine, but also stimulating exogenous iron absorption from food.  
In general, cells have protective mechanisms to attenuate harm caused by ROS and the oxidative 
process. These mechanisms include enzymes like SOD (Superoxide Dismutase), catalase, glutathione 
peroxidase  (which  removes  H2O2), glutathione transferase, ferritine (removes metals  like iron that 
promotes  oxidative  stress),  and  low  molecular  weight  antioxidants  such  as  vitamin  E,  vitamin  C, 
vitamin  A,  uric  acid,  and  bulirubin.  However,  the  production  of  oxidative  species  and  reduced 
equivalents  is  more  elevated  than  defense  mechanisms,  due  to  the  fact  that  alcohol  inhibits  
antioxidants [30]. Int. J. Environ. Res. Public Health 2010, 7                 
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4.1. Clinical Presentation of Alcoholic Liver Disease 
There is a wide variety of clinical presentations of ALD. Symptoms depend on the severity and 
stage of liver injury. Liver steatosis is the first structural change in liver secondary to chronic ethanol 
consumption. There are no clinical symptoms except for hepatomegaly. At the onset of the disease, 
steatosis is a typical finding, constituting the mildest form of ALD. It is a benign entity and the only 
clinical symptom in abdominal examination is the finding of an enlarged and tender liver. As damage 
progresses, the architecture of liver parenchyma changes inducing hepatic fibrosis due to increased 
collagen  deposit.  At  this  stage,  patients  might  suffer  decompensated  ALD  presenting  alcoholic 
hepatitis (AH).  
AH is an acute liver inflammation in response to constant injury. The cardinal sign of the disease is 
the rapid onset of jaundice. Other common signs include fever, ascities and proximal muscle loss. The 
most  common  symptoms  and  clinical  signs  in  alcoholic  hepatitis  include  swollen  liver,  nausea, 
vomiting and abdominal pain [31]. The diagnosis is based on a history of heavy alcohol use, jaundice, 
and the absence of other possible causes of hepatitis [6]. It is usually diagnosed when the liver biopsy 
indicates  inflammatory  changes,  hepatic  degeneration,  fibrosis,  and  other  cellular  changes.  The 
combination of elevated aspartate aminotransferase level (but <300 IU per milliliter) and a ratio of the 
aspartate aminotransferase level to the alanine aminotransferase level greater than 2, a total serum 
bilirubin level above 5 mg per deciliter (86 μmol per liter), an elevated INR, and neutrophilia in a 
patient with ascites and a history of heavy alcohol use, is indicative of alcoholic hepatitis until proven 
otherwise. Patients with liver failure resulting from alcoholic liver disease who do not recover within 
the first 3 months of abstinence are unlikely to survive [6]. 
When cirrhosis has developed, clinical signs include palmar erythema, contractures in the finger 
muscles caused by toxic effects of fibrous changes, white nails, ―drummer‖ fingers, liver enlargement 
or inflammation and fatty infiltration [32]. The clinical presentation is florid and it appears in advanced 
stages so it is advisable to perform routine liver function tests to patients with a history of ingesting 
quantities of alcohol capable of increasing health vulnerability, according to WHO recommendations 
on intake grams of alcohol. 
Cirrhosis might be manifested by encephalopathy, which is a clinical manifestation of a severe form 
of  liver  disease,  as  well  as  malnutrition  status  and  altered  liver  function  tests  such  as  marked 
prolongation of prothrombin time values, elevation in serum  bilirubin above 25 mg/dL, depressed 
serum  albumin,  and  elevated  serum  creatinine.  Portal  hypertension,  hepatorenal  syndrome,  and 
esophageal varices are the major causes of clinical complications and mortality in ALD [32]. 
5. Diagnostic Tests 
5.1. Steatosis and Steatohepatitis 
Steatosis can be determined with a good level of accuracy by using noninvasive imaging techniques. 
Currently,  there  is  no  available  noninvasive  diagnostic  test  to  distinguish  between  steatosis  from 
steatohepatitis or to fibrosis stage [33]. Therefore, liver biopsy remains a useful tool to establish the 
diagnosis  and  to  exclude  other  liver  disease  remaining  the  only  instrument  capable  to  provide 
prognostic information by staging and grading these diseases. Alcoholic steatohepatitis is a progressive Int. J. Environ. Res. Public Health 2010, 7                 
 
 
1880 
form  of  alcoholic  liver  disease  and  can  evolve  into  cirrhosis.  The  currently  accepted  minimum 
diagnostic criteria for steatohepatitis include steatosis, lobular inflammation, and hepatocellular injury, 
but fibrosis must be absent. Histologically, hepatocellular injury in fatty liver disease usually occurs in 
the form of ballooning, but it might also present apoptotic (acidophilic) bodies and lytic necrosis [34]. 
When there is a good quantity of neutrophils, diagnostic points out to an alcoholic etiology. Another 
mechanism seems to be sinusoidal collagen formation which results from HSC activation. 
5.2. Alcoholic Hepatitis 
Alcoholic  hepatitis  is  histologically  characterized  by  hepatocellular  injury  with  ballooned 
hepatocytes. Some of which contain steatosis, whereas others may contain intracellular, amorphous, 
eosinophilic inclusions called Mallory bodies, which are often surrounded by neutrophils [6].  
Hepatic  ultrasonography  is  useful  in  identifying  hepatic  abscess,  cryptogenic  hepatocellular 
carcinoma, and biliary obstruction, each of which may mimic alcoholic hepatitis. Ultrasonography can 
also be combined with aspiration of ascites. Doppler flow studies may be useful, since an elevated peak 
systolic velocity or an increase in the diameter of the hepatic artery may help confirm the diagnosis [3]. 
5.3. Fibrosis and Cirrhosis 
The  characteristic  pattern  of  fibrosis  in  non-cirrhotic  patients  with  steatohepatitis  follows  a 
pericellular/perisinusoidal  architecture  as  the  result  of  collagen  deposition  in  the  space  of  Disse  
(Figure 3) [35]. Perivenular fibrosis, periportal fibrosis, and cirrhosis, are typical features of alcoholic 
fibrosis and often coexist with the findings of alcoholic hepatitis. Biomarkers are useful in advanced 
liver injury but almost useless in the diagnosis of earlier tissular changes. 
Figure 3. Steatosis (black arrows) with lipidic cytoplasmic inclusions, it is reversible as 
long as the harmful stimulus is removed. Nodules circumscribed by fibrous tissue with 
collagen deposition (red arrows). 
 
 
Emergent new imaging modalities could provide more detailed information about hepatic tissue or 
even replace biopsy. However, currently there is no method to overpass the specificity of biopsy which, Int. J. Environ. Res. Public Health 2010, 7                 
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although  has  disadvantages  such  as  cost,  invasiveness,  sampling  errors,  pain,  and  bleeding  risk, 
provides an accurate staging of liver fibrosis, grade of necroinflammation, steatosis, iron overload, and 
comorbidities (i.e., autoimmunity) [36]. 
Recently FibroTest and FibroScan have been used as alternative diagnostic tools. Different studies 
have demonstrated their efficacy in clinical practice. Nonetheless, liver biopsy is still the gold standard 
to assess liver fibrosis.  
6. Complications 
High amount of chronic consumption pattern of ethanol increases the risk to develop other health 
problems. This pattern has a wide variety of adverse effects. It has been already described that ALD 
involves significant crosstalk among intracellular signaling events in the liver. Overall, inflammatory 
and innate immune responses in Kupffer cells are activated by elevated gut-derived plasma endotoxin 
levels [6]. It increases ROS which induces damage and metabolites production, such as acetaldehyde or 
lipid  peroxidation  products,  that  contribute  to  activation  of  HSC  (the  key  cell  type  involved 
in liver fibrosis)  [21].  Complications  start  when  these  events  diminish  the  functional  hepatocytes. 
Considering all patients with ALD as a single group, the average 1- and 5-year survival rates are 
approximately 80 and 50%, respectively [28]. Liver cirrhosis is the most severe form of ALD. Scar 
tissue  replaces  normal  hepatocytes,  disrupting  blood  flow.  When  the  liver  becomes  fibrotic  and 
cirrhotic, the number of functional hepatocytes decreases, and the liver loses its capacity to remove 
toxic substances from the blood [32]. Patients with cirrhosis and superimposed alcoholic hepatitis had 
a 4-year mortality greater than 60%. The prognosis of individual patients with ALD depends on the 
degree of pathological injury, the patient's nutritional status, the presence of complications of advanced 
disease, other comorbid conditions, such as HCV infection, and the patient’s inability to eliminate 
destructive drinking patterns. Alcoholic cirrhosis also appears to be an independent risk factor for 
hepatocellular  carcinoma  [34].  One  month  mortality  in  patients  with  spontaneous  hepatic 
encephalopathy  is  approximately  50%  and  75%  in  those  with  hepatorenal  syndrome;  the  median 
survival of patients with hepatorenal syndrome is less than two weeks. Comparing alcoholic cirrhosis 
to other etiologies, it is known that alcohol in Japanese society accounts for 13.6 percent of all cases of 
cirrhosis [11] while Hepatitis B virus (HBV) and HCV infection account for 13.9% and 60.9% of cases 
respectively.  Other  causes  were  primary  biliary  cirrhosis  with  2.4%  and  autoimmune  hepatitis  
with 1.9% [37]. 
Alcoholic hepatitis is perhaps the most overwhelming manifestation of alcoholic liver disease. Up 
to 40% of patients with severe alcoholic hepatitis die within the first 6 months after the onset of the 
clinical syndrome. It is well known that more severe forms of alcoholic hepatitis are associated with 
higher  mortality  rates  [38].  Among  alcoholic  hepatitis  signs  jaundice  and  fever  may  resolve  in 
alcoholic hepatitis within several weeks after discontinuation of alcohol intake, but ascites and hepatic 
encephalopathy might persist for months to years. Mortality rate in alcoholic hepatitis is about 50% in 
severe cases. If the heavy drinking pattern continues, 40 percent will develop cirrhosis. When clinical 
symptoms of encephalopathy appear, ammonia levels in the brain may increase more than twenty fold, 
this happens in patients with advanced stages of encephalopathy, resulting from chronic liver failure. Int. J. Environ. Res. Public Health 2010, 7                 
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Ammonia  remains  the  key  gut-derived  neurotoxin  implicated  in  the  pathogenesis  of  hepatic 
encephalopathy [39]. 
7. Current Treatment 
There is a wide range of therapeutic options for treating ALD and alcohol use disorders. The aim of 
all therapeutic strategies for ALD is to improve liver function. In alcoholic patients the goal attempts to 
reduce ethanol intake significantly, looking forward abstinence, thus avoiding further hepatic damage.  
7.1. Alcoholic Liver Disease 
Prognosis of individual patients with ALD depends on the degree of histological injury, patient’s 
nutritional status, presence of complications of advanced disease, other comorbid conditions such as 
HCV infection, and the patient's ability to eradicate destructive drinking patterns. The cornerstone in 
ALD  therapy  is  a  daily  life  style  modification,  including  drinking  cessation  and  treatment  of 
decompensation, if appropriate. Abstinence from alcohol is vital in order to prevent further ongoing 
liver injury, fibrosis, and possibly hepatocellular carcinoma [33]. 
7.1.1. Nutrition 
Several studies support the notion that nutritional status is a determinant factor in the outcome after 
any  therapy.  Nutritional  intervention  has  shown  to  play  a  positive  role  on  both,  in-patient  and  
out-patient basis. Data has described patients with alcoholic liver injury who voluntarily consumed  
>3,000 kcal/ day had virtually no mortality, whereas those consuming <1,000 kcal/day had a mortality 
greater than 80% at 6-month. Moreover, the undernourishment degree in cirrhosis was correlated with 
the development of severe complications such as encephalopathy, ascites and hepatorenal syndrome. 
Jonas et al. found that alcoholic fatty liver decreased significantly in rats with fatty acids supplemented 
diet, this was observed when oxidative/nitrosative levels were normalized in rats fed with alcohol-fatty 
acids-supplementes  diet  [40].  The  molecular  mechanism  of  DHA/AA,  (decosahexaenoic 
acid/arachidonic acid) essential fatty acids, against liver steatosis is poorly understood. However, it has 
been observed that steatosis increases in diets with greater amounts of polyunsaturated fatty acids. This 
fact indicates a sharpened threshold between therapeutic and harmful effects [5]. In cirrhotic patients it 
has been demonstrated that a nutritious diet improved the 5-year outcome compared with patients 
consuming an inadequate diet. 
7.1.2. Pharmacotherapy 
The progression of ALD continues according to the amount of alcohol consumed. Complications 
appear when there is a considerable liver fibrosis tissue, few functional hepatocytes, and when chronic 
inflammation  affects  the  structure  and  function  of  the  liver.  When  progression  renders  alcoholic 
hepatitis, corticosteroids are widely used in selected patients and treatment with pentoxifylline appears 
to be a promising anti-inflammatory therapy. Recent studies have indicated anti-TNFα therapy, at least 
for alcoholic hepatitis, although further clinical trials must be designed due to the disparity in the 
results  of  some  research  data.  However  antioxidant  therapy,  alone  or  in  combination  with Int. J. Environ. Res. Public Health 2010, 7                 
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corticosteroids, does not improve 6-month survival in severe alcoholic hepatitis [30]. Our own studies 
with  pirfenidone  have  suggested  an  important  anti-inflammatory  effect  with  ALD  patients 
(Armendariz-Borunda, et al., unpublished results). 
The treatment of alcoholic hepatitis is largely symptomatic, emphasizing alcohol abstinence and 
meticulous attention to nutritional status. Specific therapies such as corticosteroids and pentoxyfiline 
need to be considered as they may reduce mortality in those patients who are at high risk of dying [41]. 
7.1.3. About transplant 
Currently, the two main indications for liver transplant are: ALD and liver failure caused by HCV 
infection both in Europe and North America. Alcoholic hepatitis remains a controversial indication for 
liver transplantation; currently the procedure is not performed in this these patients owing to the fact 
that they continue consuming alcoholic beverages. Furthermore, it is required a period of abstinence as 
a  rule  before  liver  transplantation  in  many  clinics.  At  the  end  of  this  period,  liver  functionality 
improves significantly in most of the cases so the process is not performed. Although it has been 
reported that transplant outcome in ALD and other entities, such as chronic HVC infection, is very 
similar, in the daily practice many transplants are interrupted for the reasons previously described [42]. 
7.2. Alcohol Use Disorders 
Alcoholism is a multifactorial entity; hence the treatment must be addressed with different strategies 
related to AD. Alcohol use disorders are treatable disorders when efficacious medicines are added to 
enhance the effects of psychosocial treatment. Due to personal, social and health impact of alcohol use 
disorders,  therapy  must  be  guided  towards  a  complete  management  including  pharmacotherapy, 
behavioral interventions and medical board. For this reason, different strategies have been developed. 
Although abstinence remains the ultimate goal in treating alcohol-dependent individuals, reducing the 
frequency of heavy drinking has the major impact on decreasing alcohol-related consequences and 
improving quality of life [43].  
7.2.1. Pharmacotherapy 
The most promising compounds appear to be those that modulate the function of opioids, glutamate 
with or without gamma-aminobutyric acid (GABA), and serotonin (5-HT) [43]. The most used and 
approved pharmacotherapy by the Food and Drug Administration of the United States is naltrexone, 
acamprosate and disulfiram. 
Naltrexone  is  an  opioid  antagonist  which  is  prescribed  for  alcoholism  treatment  [44].  Oral 
naltrexone and naltrexone depot formulations have generally demonstrated efficacy in treating AD, but 
with small effect. Treatment with naltrexone works for some individuals, but not for everyone. It has 
been proved a functional polymorphism of the μ-opioid receptor (OPRM1) gene that might predict 
naltrexone response. Anton et al. demonstrated the relationship between the functionally significant 
OPRM1 Asp40 allele and the response to naltrexone in alcoholic patients. Carriers of the Asp40 allele 
had an increased percentage of abstinent days (P = 07) and a decreased percentage of heavy drinking 
days (P = 0.04). The homozygous Asn40/Asn40 genotype showed no medication differences [45]. Int. J. Environ. Res. Public Health 2010, 7                 
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GABA  and  glutamate  systems  are  particularly  sensitive  to  alcohol  effects,  showing  adaptation 
during the course of long-term alcohol exposure [46], for this reason receptor agonists have been 
studied as therapy targets for alcoholism. The limitations using these drugs lay on the changes in the 
gabaergic system, more specifically in the GABA A receptors in rats after chronic alcohol feeding. 
Among the new promising drugs for alcoholism we point to topiramate. It facilitates inhibitory GABA  
A-mediated currents at non-benzodiazepine sites on the GABA A receptor [43].  
Baclofen is a GABA B receptor agonist which has demonstrated good outcome in small clinical 
trials,  however  further  research  is  needed.  Although  neither  topiramate  nor  baclofen  have  been 
approved by the FDA, these are among the most promising drugs, with a medium effect size in clinical 
trials.  Furthermore  serotonergic  agents  such  as  selective  serotonin  reuptake  inhibitors  and  the 
serotonin-3  receptor  antagonist,  ondansetron,  appear  to  be  efficacious  only  among  certain  genetic 
subtypes of alcoholics [43]. Biological pathway of GABA is probably involved in AD, a key area for 
proteomics which consists in a biomarker discovery that could correlate protein expression with the 
treatment outcome or global prognosis of the disease [47]. 
Duloxetine  is  a  selective  serotonin/norepineprhine  reuptake  inhibitor  (SSNRI)  and  has  been 
proposed as a new therapy for alcohol use disorders. The results in rats treated with duloxetine showed 
robust reductions  in  alcohol consumption. Post-hoc analysis indicated that all doses of duloxetine 
significantly suppressed binge-like alcohol intake (P < 0.05) in all cases [44]. Nonetheless relapse in 
drinking and craving in the postdetoxification period is noticed, more than if treated with gabapentin. 
Disulfiram  inhibits  aldehyde  dehydrogenase  and  prevents  the  metabolism  of  alcohol’s  primary 
metabolite, acetaldehyde. The accumulation of acetaldehyde in the blood causes unpleasant effects. 
This drug has been accepted by the FDA since 1940 for treating AD, although craving for alcohol is 
not reduced and it has been related to toxicity and severe adverse effects. However it is still widely 
used for the treatment of alcoholism. 
Johnson et al. report that acamprosate has demonstrated efficacy for treating AD in European trials, 
but not so in the United States, with up to 70% of patients resuming drinking within one year. The use 
of acamprosate thus presents inconclusive results. It has been approved by the FDA, however it hasn’t 
shown positive results when comparing its effects with placebo. Unlike in the U.S., European studies 
show some efficacy in the use of acamprosate [43]. 
In the COMBINE study, data show that patients receiving treatment with naltrexone, combined 
behavioral intervention or both, fared better on drinking outcomes, whereas acamprosate showed no 
evidence of efficacy, with or without combined behavioral intervention [48]. New pharmacological 
agents that inhibit 5-HT reuptake from the synapse, reduce the voluntary consumption of ethanol. 
7.2.2. Alcoholics anonymous 
Alcoholics Anonymous (AA) is the most commonly used program for substance abuse recovery and 
one of the few models to demonstrate positive abstinence outcomes. Social support is a mechanism in 
the effectiveness of AA in promoting a sober lifestyle and worldwide membership is estimated at over 
2,000,000 in 150 countries. Some studies reported that the participation of AA was linked to positive 
drinking outcomes and modestly related to better psychological health, social functioning, employment 
situation, and legal situation [49]. Int. J. Environ. Res. Public Health 2010, 7                 
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8. Conclusions 
Ethanol consumption is widely accepted worldwide and it is sometimes traduced into substance 
abuse.  It  causes  global  public  health  problems,  covering  social  aspects  as  well  as  psychological, 
economical and family ones, among others.  
When alcohol consumption affects an individual´ s health, molecular mechanisms inducing liver 
damage begin to occur. These processes have been described broadly and therapies developed for these 
diseases are focused on avoiding alcohol abuse and improvement of liver function, once a diagnosis of 
ALD has been made. 
Nevertheless, there are genetic factors that could predispose to the development of alcoholism or 
ALD.  The  identification  of  certain  polymorphisms  associated  to  these  entities  has  been  possible. 
Currently, there is a lengthy list of treatment strategies. Both conditions have multifactorial origin, so 
each factor involved is a target for the development of new therapies. New drug research is needed 
since  currently  available  treatments  are  not  as  effective  as  expected,  for  after  a  year  of  alcohol 
consumption cessation, pathological drinking patterns tend to reappear.  
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